View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Dec. 31, 2015	Apr. 26, 2016
Document Type	10-Q
Amendment Flag	true
Amendment Description	Helius Medical Technologies, Inc. (the “Company”) is filing this amendment on Form 10-Q/A (this “Amendment”) to amend its Quarterly Report on Form 10-Q for the nine months ended December 31, 2015, as filed on February 16, 2016 (the “Original Filing”), to restate its interim condensed consolidated financial statements as of and for the nine months ended December 31, 2015, as a result of an error in the classification of warrants issued in private placements conducted in April, June, and July of 2015. The Company previously recorded the issuance of warrants in private placements conducted in April, June, and July of 2015 as equity instruments instead of as liabilities. The warrant exercise prices are denominated in U.S. dollars whereas the functional currency of the Company is the Canadian dollar; as such, the settlement of the warrants fails the fixed for fixed criteria of ASC 815 and they are required to be recorded as a liability at their fair value on inception. The warrant liability is required to be re-measured at its fair value on each reporting date with the changes in fair value recorded in the Company’s Statement of Comprehensive Loss. See Note 13 “Restatement of Previously Issued Financial Statements” to the Company’s restated interim condensed consolidated financial statements contained in this Amendment.In connection with the Original Filing, under the direction of our Chief Executive Officer and our Chief Financial Officer, our management evaluated our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, and concluded that our disclosure controls and procedures were ineffective as of December 31, 2015. Subsequently, the Company’s management has determined that the improper design of controls with respect to the calculation of the fair value of the Company’s warrants was a deficiency in its internal control over financial reporting resulting from the material weakness identified at December 31, 2015.Except as required to reflect the effects of the corrections for the items above and certain note disclosures, no additional modifications or updates have been made to the Original Filing and are set forth in this Amendment. Information not affected by these corrections remains unchanged and reflects the disclosure made at the time of the Original Filing. This Amendment does not describe other events occurring after the Original Filing, including exhibits, or modify or update those disclosures affected by subsequent events. This Amendment should be read in conjunction with the Company’s filings made with the Securities and Exchange Commission subsequent to the filing of the Original Filing, as information in such reports and documents may update or supersede certain information contained in this Amendment.The certifications of the Company’s Chief Executive Officer and Chief Financial Officer are attached to this Amendment as Exhibits 31.1, 31.2, and 32.1 respectively.
Document Period End Date	Dec. 31, 2015
Trading Symbol	hsm
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		81,408,209
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3

Interim Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 4,350,350	$ 418,893
Short-term investment	0	378,000
Receivables	121,586	8,833
Prepaid expenses	783,562	410,621
Total current assets	5,255,498	1,216,347
TOTAL ASSETS	5,255,498	1,216,347
Current liabilities
Accounts payable and accrued liabilities	1,413,579	1,197,804
Obligation to issue shares and warrants	5,000,000	0
Total current liabilities	6,413,579	1,197,804
Derivative liability	898,128	1,581,444
TOTAL LIABILITIES	7,311,707	2,779,248
CAPITAL DEFICIT
Common stock (Unlimited Class A common shares authorized); (66,637,653 shares outstanding at December 31, 2015 and 63,104,788 shares outstanding at March 31, 2015)	20,125,864	16,358,093
Additional paid-in capital	2,155,199	2,434,552
Shares to be issued	0	39,545
Accumulated other comprehensive income	(1,862,329)	(971,640)
Accumulated deficit	(22,474,943)	(19,423,451)
TOTAL CAPITAL DEFICIT	(2,056,209)	(1,562,901)
TOTAL LIABILITIES & CAPITAL DEFICIT	$ 5,255,498	$ 1,216,347

Interim Condensed Consolidated Balance Sheets (Parenthetical) - shares	Dec. 31, 2015	Mar. 31, 2015
Common Stock, Shares Authorized
Common Stock, Shares, Outstanding	66,637,653	63,104,788

Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Operating Expenses
Advertising, marketing & investor relations	$ 161,594	$ 175,325	$ 710,175	$ 579,507
Audit & accounting	36,976	4,457	141,176	45,938
Consulting fees	59,504	901,190	140,498	1,167,543
Insurance	30,018	22,287	90,022	52,060
Legal fees	761,752	500,028	1,260,798	1,064,453
Meals & travel	118,155	102,098	245,825	209,150
Office & general	30,369	45,466	83,133	163,762
Research & development	1,291,605	1,191,806	2,664,063	3,196,346
Transfer agent & regulatory	35,635	17,242	84,587	76,215
Wages and salaries	315,049	132,119	981,827	684,375
Loss from operations	(2,840,657)	(3,092,018)	(6,402,104)	(7,239,349)
Other items
Interest and accretion expense	(26,108)	0	(26,108)	(176,488)
Interest and other income	122,101	9,415	149,849	20,036
Change in fair value of derivative liability	(293,698)	(76,536)	2,113,391	(670,790)
Foreign exchange	337,593	680,578	845,146	267,950
Gain on extinguishment of debt	268,334	0	268,334	0
Total other items	408,222	613,457	3,350,612	(559,292)
Net loss for the period	(2,432,435)	(2,478,561)	(3,051,492)	(7,798,641)
Other comprehensive income (loss)
Translation adjustments	(363,796)	(707,875)	(890,689)	(395,030)
Comprehensive loss for the period	$ (2,796,231)	$ (3,186,436)	$ (3,942,181)	$ (8,193,671)
Net loss per share
Basic	$ (0.04)	$ (0.04)	$ (0.05)	$ (0.14)
Diluted	$ (0.04)	$ (0.04)	$ (0.06)	$ (0.14)
Weighted average shares outstanding
Basic	64,958,069	63,104,788	64,646,096	55,066,317
Diluted	64,958,069	63,104,788	65,180,918	55,066,317

Interim Condensed Consolidated Statements of Capital Equity (Deficit) - 9 months ended Dec. 31, 2015 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Accumulated other comprehensive income (loss)[Member]	Total
Beginning Balance at Mar. 31, 2015	$ 16,358,093	$ 2,434,552	$ 39,545	$ (19,423,451)	$ (971,640)	$ (1,562,901)
Beginning Balance (Shares) at Mar. 31, 2015	63,104,788
Exercise of finders warrants	$ 11,926					11,926
Exercise of finders warrants (Shares)	14,400
Issuance of common stock for private placement	$ 1,465,524					1,465,524
Issuance of common stock for private placement (Shares)	849,273
Issuance of common stock for private placement 2	$ 585,702		$ (39,545)			546,157
Issuance of common stock for private placement 2 (Shares)	335,463
Issuance of common stock for private placement 3	$ 233,806					233,806
Issuance of common stock for private placement 3 (Shares)	125,756
Stock option exercise	$ 42,500					42,500
Stock option exercise (Shares)	94,640
Fair value of options exercised	$ 20,454	(20,454)
Issuance of common stock as bonus shares	$ 23,959					23,959
Issuance of common stock as bonus shares (Shares)	30,000
Issuance of common stock for convertible note	$ 1,525,000					1,525,000
Issuance of common stock for convertible note (Shares)	2,083,333
Share issuance cost	$ (141,100)					(141,100)
Stock-based compensation on 3,370,000 options granted		(84,550)				(84,550)
Stock-based compensation on 400,000 options granted		167,417				167,417
Stock-based compensation on 100,000 options granted 1		28,681				28,681
Stock-based compensation on 100,000 options granted 2		28,440				28,440
Stock-based compensation on 50,000 options granted		6,880				6,880
Stock-based compensation on 750,000 options granted		66,625				66,625
Stock-based compensation on 950,000 options granted		206,461				206,461
Stock-based compensation on 100,000 options granted 3		12,032				12,032
Fair value of non-employee vested options reallocated to derivative liability		(690,885)				(690,885)
Net loss for the period				(3,051,492)		(3,051,492)
Translation adjustments					(890,689)	(890,689)
Ending Balance at Dec. 31, 2015	$ 20,125,864	$ 2,155,199		$ (22,474,943)	$ (1,862,329)	$ (2,056,209)
Ending Balance (Shares) at Dec. 31, 2015	66,637,653

Interim Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss for the period	$ (3,051,492)	$ (7,798,641)
Items not involving cash:
Change in fair value of derivative liability	(2,113,391)	670,790
Accretion	23,959	176,488
Stock-based compensation	431,986	1,970,345
Gain on extinguishment of debt	(268,334)	0
Changes in non-cash working capital items:
Receivables	(119,567)	(2,035)
Accounts Payable	128,457	975,694
Prepaid expenses	(384,629)	(150,364)
Foreign exchange re-measurement	(901,518)	(222,244)
Net cash used in operating activities	(6,254,529)	(4,379,967)
Cash flows from investing activities
Short term investment	378,000	0
Net cash provided by investing activities	378,000	0
Cash flows from financing activities
Issuance of share capital	2,299,913	7,017,009
Issuance of warrants	532,523	0
Share issuance cost	(141,100)	(379,806)
Convertible debenture and credit facility proceeds	7,000,000	633,195
Net cash provided by financing activities	9,691,336	7,270,398
Effect of foreign exchange rate changes on cash	116,650	0
Net change in cash and cash equivalents	3,931,457	2,890,431
Cash and cash equivalents, beginning of the period	418,893	15,968
Cash and cash equivalents, end of the period	4,350,350	2,906,399
Supplemental cash flow information
Interest paid in cash	1,644	11,144
Income taxes paid in cash	$ 0	$ 0

BASIS OF PRESENTATION

9 Months Ended

Dec. 31, 2015

BASIS OF PRESENTATION [Text Block]

1. BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements of Helius Medical Technologies Inc. (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended March 31, 2015 in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2015, and as subsequently amended and refiled on January 11, 2016. The unaudited condensed consolidated interim financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the consolidated financial position of the Company at December 31, 2015, and the consolidated results of operations for the three and nine months ended December 31, 2015, and consolidated statements of cash flows for the nine months ended December 31, 2015. All intercompany accounts and transactions have been eliminated. It should be understood that accounting measures at interim dates inherently involve greater reliance on estimates than at year end. The results of operations for the three and nine months ended December 31, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Dec. 31, 2015

SIGNIFICANT ACCOUNTING POLICIES [Text Block]

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Liquidity

The Company has incurred a net loss of $3,051,492 for the nine months ended December 31, 2015 and, as of December 31, 2015, the Company has an accumulated deficit of $22,474,943 (March 31, 2015 - $19,423,451). Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. While the Company had cash and cash equivalents of $4,350,350 as of December 31, 2015 (March 31, 2015 - $418,893), management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

Fair Value of Financial Assets and Liabilities

The Company’s financial instruments consist primarily of cash and cash equivalents, accounts payable and accrued liabilities, and an obligation to issue shares and warrants. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value;

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Level 3 – Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

The Company had certain Level 3 liabilities required to be recorded at fair value on a recurring basis in accordance with US GAAP as at December 31, 2015. As at December 31, 2015, the Company’s Level 3 liabilities consisted of warrants and share purchase options awarded to non-employees. The resulting Level 3 liabilities have no active market and are required to be measured at their fair value each reporting period based on information that is unobservable.

A summary of the Company’s Level 3 liabilities for the periods ended December 31, 2015 and 2014 are as follows:

Non-Employee Options

	Nine months ended		Nine months ended
	December 31, 2015		December 31, 2014
	$		$
Beginning fair value	1,581,444		-
Issuance of warrants and non-employee options	-		767,879
Reallocation of vested non-employee options	690,885		42,227
Change in fair value	(1,725,520	)	670,790
Ending fair value of non-employee options	546,809		1,480,896

Embedded Conversion feature

	Nine months ended		Nine months ended
	December 31, 2015		December 31, 2014
	$		$
Beginning fair value	-		-
Bifurcation of embedded conversion feature	425,208		-
Settlement of convertible debt	(425,208	)	-
Ending fair value of embedded conversion feature	-		-

Warrants

Beginning fair value	-		-
Issuance of warrants	739,190		-
Change in fair value	(387,871	)	-
Ending fair value of warrants	351,319		-
Ending fair value of Level 3 liability	898,128		1,480,896

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). There were no assets or liabilities measured at fair value on a non-recurring basis during the periods ended December 31, 2015 and December 31, 2014.

Basic and Diluted Income (Loss) per Share

Earnings or loss per share (“EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income (loss) by the weighted-average of all potentially dilutive shares of common stock that were outstanding during the periods presented. The number of shares potentially issuable at December 31, 2015 upon the exercise or conversion of share purchase warrants, share purchase options and conversion of convertible debentures totaled 19,633,969.

The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period.

EPS for convertible debt is calculated under the “if-converted” method. Under the if converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt.

The basic and diluted earnings per share for the three and nine months ended December 31, 2015 and 2014 were calculated as follows:

		Three months ended						Nine months ended
		December			December			December			December
		31, 2015			31, 2014			31, 2015			31, 2014
		(Restated –			(Restated –			(Restated –			(Restated –
		Note 13)			Note 13)			Note 13)			Note 13)
Basic Numerator
Net loss for the period	$	(2,432,435	)	$	(2,478,561	)	$	(3,051,492	)	$	(7,798,641	)
Denominator
Weighted average common shares outstanding		64,958,069			63,104,788			64,646,096			55,066,317

Basic net loss per share	$	(0.04	)	$	(0.04	)	$	(0.05	)	$	(0.14	)
Diluted Numerator
Net loss for diluted income per share	$	(2,432,435	)	$	(2,478,561	)	$	(3,051,492	)	$	(7,798,641	)
Gain in fair value of options		-			-			(1,094,449	)		-
Loss available to common stockholders	$	(2,432,435	)	$	(2,478,561	)	$	(4,145,941	)	$	(7,798,641	)
Denominator
Weighted average common shares outstanding		64,958,069			63,104,788			64,646,096			55,066,317
Potential share issuances
Common share options		-			-			534,822			-
Common share warrants		-			-			-			-
Weighted average number of common shares outstanding used in computing diluted earnings per share		64,958,069			63,104,788			65,180,918			55,066,317

Diluted earnings per share	$	(0.04	)	$	(0.04	)	$	(0.06	)	$	(0.14	)

Recent Accounting Pronouncements

In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In May, 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows.

In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835-30). This guidance is to simplify the presentation of debt issuance costs by recognizing a debt liability in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. The amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact of adoption of this new accounting pronouncement on its financial statements.

CONVERTIBLE DEBENTURE

9 Months Ended

Dec. 31, 2015

CONVERTIBLE DEBENTURE [Text Block]

3. CONVERTIBLE DEBENTURE

On February 19, 2014, the Company entered into a securities purchase agreement where the Company agreed to sell and issue a note with annual simple interest at 8% (the “Debenture”). A total of $1,000,100 in principal had been received.

On June 13, 2014, the Debenture matured on the closing of the Company’s qualified financing. Upon completion of the qualified financing, the Debenture automatically converted into equity securities of the Company at a price per share equal to 85% of the price per share of the qualified financing. The conversion option of the Debenture was accounted for as a contingent beneficial conversion feature valued at $176,488 which was recorded as interest expense in the Statement of Comprehensive Loss on settlement of the contingency.

PROMISSORY NOTE

9 Months Ended

Dec. 31, 2015

PROMISSORY NOTE [Text Block]

4. PROMISSORY NOTE

On September 8, 2015, the Company received $200,000 in exchange for the issuance of a promissory note (the “Promissory Note”). The Promissory Note was to be repaid six months from the date of issuance with interest accruing at the rate of 6% per annum for the first three months and 10% per annum thereafter. In addition, the lender was entitled to receive 30,000 common shares of the Company on the date of the Promissory Note (the “Bonus Shares”) and an additional 30,000 common shares every three months thereafter as long as the principal of the loan remained outstanding. During the nine months ended December 31, 2015, the Company issued the lender 30,000 Bonus Shares valued at $23,959 based on their quoted market to the lender. This amount was recorded as a debt discount of the Promissory Note at issuance and was being amortized using the effective interest method over the term of the Promissory Note.

On October 28, 2015, the Company repaid the Promissory Note in its entirety, along with accrued interest of $1,644. The remaining debt discount was immediately recorded as interest expense on the date of repayment.

COMMON STOCK

9 Months Ended

Dec. 31, 2015

COMMON STOCK [Text Block]

5. COMMON STOCK

On April 30, 2015 the Company closed a non-brokered private placement (the “First Financing”) raising gross proceeds of $1,825,937 by the issuance of 849,273 units (each a “First Financing Unit”) at a price of $2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder’s fee of $84,074 in connection with this First Financing, as well as 27,396 finder’s warrants (the “First Financing Finder’s Warrants”). Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

On June 26, 2015 the Company closed a non-brokered private placement (the “Second Financing”) raising gross proceeds of $721,243 by the issuance of 335,463 units (each a “Second Financing Unit”) at a price of $2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder’s fee of $40,803 in connection with this Second Financing, as well as 18,978 finder’s warrants (the “Second Financing Finder’s Warrants”). Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

On July 17, 2015 the Company closed a non-brokered private placement (the “Third Financing”) raising gross proceeds of $270,375 by the issuance of 125,756 units (each a “Third Financing Unit”) at a price of $2.15 per Third Financing Unit. Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Third Financing Warrant”). Each whole Third Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Third Financing. The Company paid a cash finder’s fee of $16,223 in connection with this Third Financing, as well as 7,545 finder’s warrants (the “Third Financing Finder’s Warrants”). Each Third Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

On October 9, 2015, in connection with an Asset Purchase Agreement, the Company entered into a US$7.0 million funding commitment with A&B Company Limited (“A&B”) in the form of a convertible promissory note. The funding commitment consisted of (i) an initial $2.0 million and (ii) an additional $5.0 million funding commitment, upon which the Company could draw down at any time or from time to time during the six-month period beginning on the issuance date of the convertible promissory note. The convertible promissory note was convertible at the option of the holder into units consisting of one share of common stock and one half share purchase warrant of the Company.

See Note 7, “Convertible Note,” regarding the warrants issued in conjunction with the repayment of the note.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

SHARE BASED PAYMENTS

9 Months Ended

Dec. 31, 2015

SHARE BASED PAYMENTS [Text Block]

6. SHARE BASED PAYMENTS

(a) Stock options

The Company has a stock option plan whereby the Company is authorized to grant up to 12,108,016 options. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company.

The continuity of stock options for the periods as at December 31, 2015 and March 31, 2015, are as follows:

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)

Balance outstanding at March 31, 2015	4,920,000		$	1.14	$	10,120,000
Exercised	(94,640	)	$	0.60		-
Granted	1,850,000			0.88		-

Balance outstanding at December 31, 2015	6,675,360		$	1.08	$	2,588,702

Balance exercisable at December 31, 2015	4,272,279		$	1.16	$	1,637,490

The options outstanding and exercisable at December 31, 2015 are as follows:

		Options
		outstanding
		remaining					Number of
Number of		contractual life		Exercise		Grant date fair	options
options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	3.46	$	0.60	$	0.23	2,346,667
155,360	June 20, 2019	3.46	$	0.60	$	0.23	124,110
100,000	July 14, 2017	1.54	$	2.52	$	1.06	100,000
450,000	December 8, 2019	3.94	$	2.92	$	1.65	450,000
100,000	December 8, 2019	3.94	$	2.92	$	1.49	66,667
400,000	December 8, 2019	3.94	$	2.96	$	1.56	300,000
100,000	March 16, 2020	4.21	$	3.20	$	1.61	33,334
50,000	August 15, 2015	4.62	$	0.98	$	0.39	16,667
750,000	October 21, 2020	4.81	$	0.87	$	0.33	187,500
550,000	October 28, 2020	4.83	$	0.84	$	0.44	550,000
400,000	October 28,2020	4.83	$	0.84	$	0.36	64,000
100,000	December 31, 2020	5.00	$	1.24	$	0.50	33,334
6,675,360							4,272,279

The fair value of stock options granted during the periods ended December 31, 2015 and 2014 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2015	December 31, 2014

Stock price	$0.822	$1.33
Exercise Price	$0.878	$1.10
Expected life	3.6 years	3.9 years
Expected volatility	67.85%	67.85%
Risk – free interest rate	0.84%	1.32%
Dividend rate	0.00%	0.00%

The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neurohabilitation Corporation (“NHC”) are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than NHC’s functional currency. Stock options awarded to non-employees that are not vested are re-measured at their respective fair values at each reporting period and accounted for as equity awards until the terms associated with their vesting requirements have been met. The changes in fair value of the unvested non-employee awards are reflected in their respective operating expense classification in the Company’s Consolidated Statement of Comprehensive Income (Loss).

The non-employee stock options and warrants that are required to be accounted for as liabilities are summarized as follows for the periods ended December 31, 2015 and March 31, 2015:

	Nine months ended December 31, 2015 $	Nine months ended December 31, 2014 $

Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	690,885	42,227
Change in fair value of non-employee stock options during the period	(725,520)	739,375

Fair value of non-employee options, end of the period	1,546,809	1,549,481

The non-employee options that have vested are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s Consolidated Statements of Loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

Share-based payments are classified in the Company’s Statement of Loss as follows for the period ended December 31, 2015 and 2014:

	Three months ended December 31, 2015 $	Nine months ended December 31, 2015 $	Three months ended December 31, 2014 $	Nine months ended December 31, 2014 $

Consulting fees	(36,300)	(45,199)	871,269	1,033,200
Research and development	315,031	57,550	239,463	578,120
Wages and salaries	52,737	419,635	(77,784)	359,025

	331,468	431,986	1,032,948	1,970,345

(b) Share Purchase Warrants

The continuity of warrants for the nine months ended December 31, 2015 is as follows:

	Number of warrants		Weighted Average Exercise Price
	CAD	US	CAD $	US $
Balance March 31, 2015	8,444,400	-	$1.00	-
Granted		1,750,831	-	2.06
Exercised	(14,400)	-	$1.00	-
Balance December 31, 2015	8,430,000	1,750,831	$1.00	2.06

The warrants outstanding and exercisable at December 31, 2015 are as follows:

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD $1.00	May 30, 2016
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020
62,878	US $3.00	July 17, 2018
7,545	US $2.15	July 17, 2020
1,041,667	US $1.44	November 10, 2018

During the nine months ended December 31, 2015, the Company issued an aggregate of 1,750,931 common stock purchase warrants that are required to be accounted for as liabilities pursuant to ASC 815 because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than the Company’s functional currency.

Pursuant to the guidance of ASC 815, warrants having an exercise price denominated in a currency other than the functional currency of the Company are required to be accounted for as liabilities are accounted for at their respective fair values, with the change in fair value recorded on the consolidated statement of operations as other income.

The warrants having an exercise price denominated in a currency other than the functional currency of the Company that are required to be accounted for as liabilities are summarized as follows for the periods ended December 31, 2015 and 2014:

	Nine months ended December 31, 2015 $	Nine months ended December 31, 2014 $

Fair value of warrants, beginning of the period	-	-
Issuance	739,190	-
Change in fair value of warrants during the period	(387,871)	-

Fair value of warrants, end of the period	351,319	-

The fair value of the warrants issued during the periods ended December 31, 2015 and 2014 were estimated using the Black-Scholes pricing model with the following weighted average assumptions:

	December 31, 2015	December 31, 2014

Stock price	$0.73	-
Exercise Price	$1.44	-
Expected life	3.0 years	-
Expected volatility	67.85%	-
Risk – free interest rate	0.96%	-
Dividend rate	0.00%	-

The warrants are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s Consolidated Statements of Loss at the end of each reporting period. The fair value of the warrants will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

CONVERTIBLE NOTE

9 Months Ended

Dec. 31, 2015

CONVERTIBLE NOTE [Text Block]

7. CONVERTIBLE NOTE

On October 9, 2015, in connection with an Asset Purchase Agreement, the Company entered into a US$7.0 million funding commitment with A&B Company Limited (“A&B”). The funding commitment consisted of (i) an initial $2.0 million in the form of a convertible promissory note and (ii) an additional $5.0 million funding commitment, upon which the Company could draw down at any time or from time to time during the six-month period beginning on the issuance date of the Note. The Note would accrue interest at a rate equal to 6% per annum, payable in cash on the due date of April 9, 2016.

The Company could elect to draw down the remaining $5.0 million commitment within six months. Such additional funding would be through the issuance of additional shares and warrants at a price based on the volume weighted average closing price of the Company’s shares of common stock.

The Note was unsecured and the initial $2 million commitment was convertible at the option of the holder into units of the Company at $0.96 per unit. Each unit would consist of one share of common stock and one half share purchase warrant exercisable at $1.44 for a period of three years from the date of issuance.

The Company could elect to draw down on the additional funding through the issuance of units of the Company at a price based on the volume weighted average closing price of the Company’s shares of common stock on the date the Company elects to draw down from the commitment (the “Draw Down Price”). Each unit would consist of one share of common stock of the Company and one half share purchase warrant. The warrant would be exercisable at the price representing a fifty percent ( 50%) premium to the Draw Down Price.

On December 29, 2015, the Company drew down the remaining $5.0 million of the commitment at a price of $0.90 per unit, with each unit consisting of one share of common stock and one half warrant exercisable at $1.35 per share for a period of three years from the date of issuance. The shares were issued subsequent to December 31, 2015.

Pursuant to the guidance of ASC 815 Derivatives and Hedging, the Company determined that the conversion feature embedded in the $2.0 million commitment under the Note was required to be bifurcated from the Note and accounted for as a liability because it was considered not to be indexed to the Company’s stock due to its exercise price being denominated in a currency other than the Company’s functional currency. Therefore, pursuant to the guidance of ASC 815-15, the Company allocated the proceeds from the issuance of the Note first to the fair value of the embedded conversion feature, with a corresponding discount allocated to the Note. The fair value of the embedded conversion feature was calculated using the Black Scholes pricing model using the following weighted average assumptions: Stock price - $0.73 ; Exercise price - $0.9877 ; Expected remaining life – 1.33 years; Volatility - 103.64%; Risk free rate of return – 0.3677% . This resulted in a debt discount of $425,208 in connection with the Note. This debt discount would be amortized using the effective interest method over the term of the Notes. During the nine months ended December 31, 2015, the Company did not record any accretion in respect of this discount, because the Note was immediately converted, as noted below.

As agreed, the Company repaid the $2.0 million Note through the issuance of 2,083,333 shares of common stock at a price of $0.96 per share and 1,041,667 warrants exercisable at $1.44 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on November 10, 2015.

As a result of the bifurcation of the embedded conversion option, for accounting purposes, two instruments were considered outstanding and, upon exercise of the contractual conversion option, extinguishment accounting has been applied. Consequently, the shares issued pursuant to the conversion are recorded at their fair value on the date of issuance, determined with reference to their quoted market price on the date of conversion. The resulting difference between the fair value of the shares issued, less the fair value of the related conversion feature and the carrying value of the related debt, is recorded as a gain or loss on the consolidated statement of operations. During the nine months ended December 31, 2015, the Company recorded a gain on extinguishment of debt of $268,334 in connection with the conversion of the Note.

On December 29, 2015, the Company received the remaining $5.0 million commitment in accordance with the terms of this agreement. In exchange, the Company issued 5,555,556 common shares and 2,777,778 warrants exercisable at $1.35 for a period of three years from the date of issuance. The shares and warrants were delivered to A&B on January 7, 2016. As a result, the balance of the $5.0 million is reflected in the Company’s financial statements as an obligation to issue shares and warrants as at December 31, 2015.

The bifurcation of the embedded conversion feature in the Note was classified as a Level 3 liability with the changes in fair value summarized as follows:


	Nine months ended December 31, 2015 $		Nine months ended December 31, 2014 $
Beginning fair value	-		-
Bifurcation of embedded conversion feature	425,208		-
Settlement of convertible debt	(425,208	)	-
Ending fair value of embedded conversion feature	-		-

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Dec. 31, 2015

COMMITMENTS AND CONTINGENCIES [Text Block]

8. COMMITMENTS AND CONTINGENCIES

(a)	The Company entered into a license agreement with Advanced NeuroRehabilitation, LLC (“ANR”) for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent- pending technology.

(b)	On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica where Ximedica will design, develop and produce PoNS™ product solution suitable for clinical trial and commercial sale. Under the program, the Company is responsible for ensuring the device is in compliance with relevant laws and regulations. The agreed budget for phase 1B of development is $499,000 ; phase 2 is $1,065,000 ; Phase 3 and 4 is $1,389,000 and 2 ^nd software development cycle is $586,000, of which $4,708,223 was expensed as research and development since inception to December 31, 2015. Invoices are to be issued monthly for work in progress. The Company can cancel the project at any time with a written notice at least 30 days prior to the intended date of cancellation. As of December 31, 2015, the Company recorded a prepaid expense of $300,000 to Ximedica which will be applied at the end of the project. During the period ended December 31, 2015, the Company incurred charges of $1,608,235 (December 31, 2014 - $2,226,283) pursuant to this agreement.

(c)	On January 5, 2015, Wicab Inc. (“Wicab”) filed a complaint against us, NHC, our director Mitchell Tyler, and our former director Yuri Danilov, and ANR in the U.S. District Court for the Western District of Wisconsin. The complaint contained various state and common law claims arising from Messrs. Danilov’s and Tyler’s prior employment with Wicab and our two issued patents for the PoNS™ device. The complaint alleged, among other things, that following their departure from Wicab, Messrs. Danilov and Tyler knowingly filed patent applications for and used ideas and inventions developed at Wicab in violation of various non-competition and confidentiality agreements, and that our two issued patents are therefore rightfully the property of Wicab. The complaint sought an unspecified amount of monetary damages, an injunction preventing us from using the ideas and inventions in the two patents, an order transferring ownership of the patents from us to Wicab, and recovery of costs and attorneys’ fees. The complaint was voluntarily dismissed without prejudice on January 14, 2015.

	On October 12, 2015, the Company received a letter from Wicab alleging that the two issued patents were invalid in view of prior art cited in the letter, including scientific publications and patent applications, and that Paul Bach-y-Rita, Wicab’s founder, should have been named as an inventor on these two issued patents. Wicab indicated in the letter that it may file reexamination or inter partes review proceedings with the U.S. Patent Office to attempt to invalidate the claims in the two issued patents. Wicab also stated that it would consider an unspecified “business solution” to resolve this matter. On December 10, 2015, representatives of each of the Company and Wicab met to discuss the parameters of a potential settlement. There can be no guarantee that a settlement will be reached. In the event that a settlement with Wicab is not reached, Wicab may file reexamination or inter partes review proceedings with the U.S. Patent Office to challenge the validity of the two issued patents. If the Company receives an adverse decision from the U.S. Patent Office in connection with these proceedings, some or all of the claims in the two patents may be invalidated or otherwise impaired, which could prevent the Company from bringing an infringement suit against a future competitor for making use of the PoNS™ technology for neurorehabilitation, and could have a material adverse effect on the Company’s business, operating results and financial condition. Wicab may also take other actions against the Company, its assets, intellectual property rights, officers, directors, employees, agents or other persons or entities which may also have a material effect on the Company’s business, operating results and financial condition. The Company believes that the possibility of an economic outlay is remote.

(d)	On January 27, 2015 we received a demand letter containing allegations that we had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainier Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages in excess of $225,000. On December 2, 2015 the Company entered into a settlement agreement with the plaintiffs for an amount of € 57,000 which was subsequently paid on January 12, 2016. The parties have since executed the settlement agreement for the aforementioned amount and the case has been dismissed without prejudice.

(e)	Under our Strategic Agreement with A&B if we fail to obtain FDA clearance for commercialization of or otherwise fail to ensure that the PoNS™ device is available for purchase by the U.S. Government by December 31, 2017, we are subject to a US$2,000,000 contract penalty payable to A&B.

RELATED PARTY TRANSACTIONS

9 Months Ended

Dec. 31, 2015

RELATED PARTY TRANSACTIONS [Text Block]

9. RELATED PARTY TRANSACTIONS

For the three and nine month period ended December 31, 2015, the Company was a party to the following related party transactions:

During the three-month period ended December 31, 2015, $295,848 (December 31, 2014 - $63,524) was included in research & development expenses as the fair value of stock-based compensation attributed to the options granted to two directors and a consultant for consulting services rendered with respect to the design and development of the PoNS™ device. During the nine-month period ended December 31, 2015, $38,367 (December 31, 2014 - $351,878) was included in research & development expenses as the fair value of stock-based compensation attributed to the options granted to two directors and a consultant for consulting services rendered with respect to the design and development of the PoNS™ device.

During the three-month period ended December 31, 2015, ($271,944) (December 31, 2014 – ($388,800)) was included in wages & salaries expenses as the fair value of stock-based compensation attributed to the options granted to directors. During the nine-month period ended December 31, 2015, $94,954 (December 31, 2014 - $48,009) was included in wages & salaries expenses as the fair value of stock-based compensation attributed to the options granted to directors.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

SOLE-SOURCE COST-SHARING AGREEMENT

9 Months Ended

Dec. 31, 2015

SOLE-SOURCE COST-SHARING AGREEMENT [Text Block]

10. SOLE-SOURCE COST-SHARING AGREEMENT

During the nine months ended December 31, 2015, the Company entered into a sole source cost sharing contract executed with the U.S. Army Medical Research and Materiel Command (“USAMRMC”). Under the terms of the contract, the USAMRMC will reimburse the Company up to a maximum of $2,996,244 representing approximately 62% of the Company’s estimated costs for the registrational trial (‘the trial”) investigating the safety and effectiveness of the portable neuromodulation stimulator for mild to moderate traumatic brain injury. The trial expires on December 31, 2016.

As of December 31, 2015, the Company has received a total of $1,372,821 in respect of expenses reimbursed.

Under the terms of the agreement, the USAMRMC may terminate their obligation at any time with 30 days written notice.

SUPPLEMENTAL CASH FLOW INFORMATION

9 Months Ended

Dec. 31, 2015

SUPPLEMENTAL CASH FLOW INFORMATION [Text Block]

11. SUPPLEMENTAL CASH FLOW INFORMATION

Investing and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows.

During the nine months ended December 31, 2015;

	i)	the Company issued 30,000 shares of common stock having a fair value of $23,959 based on their quoted market price as a bonus in connection with the advance of a loan;

	ii)	the Company issued 2,083,333 common shares having a fair value of $1,525,000 based on their quoted market price upon the conversion of a convertible note payable in the amount of $2,000,000. Also, in connection with this debt conversion, the Company also issued 1,041,667 share purchase warrants having a fair value of $206,667 at their inception.

	iii)	the Company reallocated $690,885 from additional paid-in capital to derivative liability in respect of the fair value of non-employee share purchase options that had vested.

During the nine months ended December 31, 2014:

	i)	the Company issued 2,564,705 common shares valued at $1,000,100 based on the carrying value of the convertible debenture upon its conversion;

	ii)	the Company recorded a beneficial conversion feature of $176,488 in respect of a qualifying transaction recorded in connection with the convertible debenture;

	iii)	The Company recorded a credit to additional paid-in capital of $162,890 representing the carrying values of the net assets acquired in a reverse merger recapitalization transaction.

These transactions have been excluded from the statement of cash flows.

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS

9 Months Ended

Dec. 31, 2015

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS [Text Block]

12. CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company’s previously issued financial statements have been restated to reflect the correction of an error in the re-measurement of non-employee stock option awards that had yet to vest. This restatement was announced in the Company’s current report on Form 8-K filed on January 11, 2016.

Previously, the Company had recorded the stock-based compensation for the period ended December 31, 2014 based on the fair value of the awards on their respective grant dates. Under the provisions of ASC 505-50, the Company is required to measure stock-based compensation for non-employees at the earlier of the performance commitment date or the date that the services have been completed. A performance commitment date exists only when the counterparty has sufficient disincentive not to complete. Otherwise, the Company is required to re-measure unvested non-employee options at their respective fair values until the services have been completed or once the options have vested. Under the terms of the Company’s stock option awards to non-employees, there were no performance disincentives. As a result the Company is required to re-measure its non-employee awards until they have vested. This also affects the calculation of the change in fair value of derivative liability which appears on the Company’s statements of comprehensive income (loss).

The correction of the error is presented in the Company’s interim condensed consolidated financial statements for the period ended December 31, 2015 as follows:

	Three months ended December 31, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$1,694,685	($793,495)	$901,190
Research and development	$952,343	$239,463	$1,191,806
Wages and salaries	$603,492	($471,373)	$132,119

Loss from operations	($4,117,423)	$1,025,405	($3,092,018)

Interest and other income	$2,845	$6,570	$9,415
Change in fair value of derivative liability	($55,589)	($20,947)	($76,536)
Foreign exchange	$687,148	($6,570)	$680,578

Net income (loss) for the period	$(3,483,019)	$1,004,458	$(2,478,561)

Comprehensive income (loss) for the period	$(4,190,894)	$1,004,458	$(3,186,436)

Basic and diluted loss per share	$(0.06)	$0.02	$(0.04)

	Nine months ended December 31, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$2,336,051	($1,168,508)	$1,167,543
Research and development	$2,668,529	$527,817	$3,196,346
Wages and salaries	$1,253,494	($569,119)	$684,375

Loss from operations	($8,449,159)	$1,209,810	($7,239,349)

Change in fair value of derivative liability	($818,382)	$147,592	($670,790)

Net loss for the period	$(9,156,043)	$1,357,402	$(7,798,641)

Comprehensive loss for the period	$(9,551,073)	$1,357,402	$(8,193,671)

Basic and diluted loss per share	$(0.17)	$0.03	$(0.14)

RESTATEMENT OF PREVIOUSLY ISSUED AND RESTATED FINANCIAL STATEMENTS

9 Months Ended

Dec. 31, 2015

RESTATEMENT OF PREVIOUSLY ISSUED AND RESTATED FINANCIAL STATEMENTS [Text Block]

13. RESTATEMENT OF PREVIOUSLY ISSUED AND RESTATED FINANCIAL STATEMENTS

The Company’s previously issued and restated financial statements have been restated to reflect the correction of an error in the classification of the warrants issued in the First Financing and the Second Financing.

Previously, the Company had recorded the First Financing Warrants, First Financing Finders Warrants, Second Financing Warrants, and Second Financing Finders Warrants (collectively, the “Warrants”) as equity instruments. Under the provisions of ASC 815-40-15, if the exercise price of an instrument is denominated in a currency other than the Company’s functional currency, the instrument shall not be considered as indexed to the Company’s own stock because it is exposed to fluctuations in foreign currency exchange rates. Instead, the instrument should be recorded as a liability at fair value through profit or loss. The functional currency of the Company is the Canadian dollar but the exercise prices of the Warrants are denominated in U.S. dollars, so under ASC 815-40-15, the Warrants must be classified as liabilities at fair value through profit or loss. As a result, the Company is required to reclassify the fair value of the Warrants from equity to liability through profit or loss.

The correction of the error is presented in the Company’s interim condensed consolidated financial statements for the period ended December 31, 2015 as follows:

	Three months ended December 31, 2015
	As reported after first restatement	Adjustment	As restated

Change in fair value of derivative liability	$(261,802)	$(31,896)	$(293,698)

Net loss for the period	($2,400,539)	$(31,896)	$(2,432,435)

Comprehensive loss for the period	$(2,764,335)	$(31,896)	$(2,796,231)

Basic gain (loss) per share	($0.04)	$-	($0.04)

Diluted gain (loss) per share	($0.04)	$-	($0.04)

	Nine months ended December 31, 2015
	As reported	Adjustment	As restated

Change in fair value of derivative liability	$1,627,844	$485,547	$2,113,391

Net loss for the period	($3,537,039)	$485,547	$(3,051,492)

Comprehensive loss for the period	$(4,427,728)	$485,547	$(3,942,181)

Basic gain (loss) per share	($0.05)	$-	($0.05)

Diluted gain (loss) per share	($0.07)	$0.01	($0.06)

	As at December 31, 2015
	As reported after first restatement	Adjustment	As Restated
Derivative liability	$830,378	$67,750	$898,128
Common stock	$20,658,387	$(532,523)	$20,125,864
Additional paid-in capital	$2,175,973	$(20,774)	$2,155,199
Accumulated deficit	$(22,960,490)	$485,547	$(22,474,943)

There was no effect on cash flow for each of the periods and therefore there has been no restatement to the consolidated statements of cash flows.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2015
Basis of Presentation and Liquidity [Policy Text Block]	Basis of Presentation and Liquidity The Company has incurred a net loss of $3,051,492 for the nine months ended December 31, 2015 and, as of December 31, 2015, the Company has an accumulated deficit of $22,474,943 (March 31, 2015 - $19,423,451). Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. While the Company had cash and cash equivalents of $4,350,350 as of December 31, 2015 (March 31, 2015 - $418,893), management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year. The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.
Fair Value of Financial Assets and Liabilities [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments consist primarily of cash and cash equivalents, accounts payable and accrued liabilities, and an obligation to issue shares and warrants. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value; Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and Level 3 – Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. Cash and cash equivalents and short-term investment are measured using Level 1 inputs.
Basic and Diluted Income (Loss) per Share [Policy Text Block]	Basic and Diluted Income (Loss) per Share Earnings or loss per share (“EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income (loss) by the weighted-average of all potentially dilutive shares of common stock that were outstanding during the periods presented. The number of shares potentially issuable at December 31, 2015 upon the exercise or conversion of share purchase warrants, share purchase options and conversion of convertible debentures totaled 19,633,969. The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period. EPS for convertible debt is calculated under the “if-converted” method. Under the if converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt.
Recent Accounting Pronouncements [Policy Text Block]	Recent Accounting Pronouncements In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. In May, 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835-30). This guidance is to simplify the presentation of debt issuance costs by recognizing a debt liability in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. The amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact of adoption of this new accounting pronouncement on its financial statements.

SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Dec. 31, 2015

Fair Value, by Balance Sheet Grouping [Table Text Block]

	Nine months ended		Nine months ended
	December 31, 2015		December 31, 2014
	$		$
Beginning fair value	1,581,444		-
Issuance of warrants and non-employee options	-		767,879
Reallocation of vested non-employee options	690,885		42,227
Change in fair value	(1,725,520	)	670,790
Ending fair value of non-employee options	546,809		1,480,896

Schedule of Conversions of Stock [Table Text Block]

	Nine months ended		Nine months ended
	December 31, 2015		December 31, 2014
	$		$
Beginning fair value	-		-
Bifurcation of embedded conversion feature	425,208		-
Settlement of convertible debt	(425,208	)	-
Ending fair value of embedded conversion feature	-		-

Schedule of Fair Value of Warrants [Table Text Block]

Beginning fair value	-		-
Issuance of warrants	739,190		-
Change in fair value	(387,871	)	-
Ending fair value of warrants	351,319		-
Ending fair value of Level 3 liability	898,128		1,480,896

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three months ended						Nine months ended
		December			December			December			December
		31, 2015			31, 2014			31, 2015			31, 2014
		(Restated –			(Restated –			(Restated –			(Restated –
		Note 13)			Note 13)			Note 13)			Note 13)
Basic Numerator
Net loss for the period	$	(2,432,435	)	$	(2,478,561	)	$	(3,051,492	)	$	(7,798,641	)
Denominator
Weighted average common shares outstanding		64,958,069			63,104,788			64,646,096			55,066,317

Basic net loss per share	$	(0.04	)	$	(0.04	)	$	(0.05	)	$	(0.14	)
Diluted Numerator
Net loss for diluted income per share	$	(2,432,435	)	$	(2,478,561	)	$	(3,051,492	)	$	(7,798,641	)
Gain in fair value of options		-			-			(1,094,449	)		-
Loss available to common stockholders	$	(2,432,435	)	$	(2,478,561	)	$	(4,145,941	)	$	(7,798,641	)
Denominator
Weighted average common shares outstanding		64,958,069			63,104,788			64,646,096			55,066,317
Potential share issuances
Common share options		-			-			534,822			-
Common share warrants		-			-			-			-
Weighted average number of common shares outstanding used in computing diluted earnings per share		64,958,069			63,104,788			65,180,918			55,066,317

Diluted earnings per share	$	(0.04	)	$	(0.04	)	$	(0.06	)	$	(0.14	)

SHARE BASED PAYMENTS (Tables)

9 Months Ended

Dec. 31, 2015

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)

Balance outstanding at March 31, 2015	4,920,000		$	1.14	$	10,120,000
Exercised	(94,640	)	$	0.60		-
Granted	1,850,000			0.88		-

Balance outstanding at December 31, 2015	6,675,360		$	1.08	$	2,588,702

Balance exercisable at December 31, 2015	4,272,279		$	1.16	$	1,637,490

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

		Options
		outstanding
		remaining					Number of
Number of		contractual life		Exercise		Grant date fair	options
options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	3.46	$	0.60	$	0.23	2,346,667
155,360	June 20, 2019	3.46	$	0.60	$	0.23	124,110
100,000	July 14, 2017	1.54	$	2.52	$	1.06	100,000
450,000	December 8, 2019	3.94	$	2.92	$	1.65	450,000
100,000	December 8, 2019	3.94	$	2.92	$	1.49	66,667
400,000	December 8, 2019	3.94	$	2.96	$	1.56	300,000
100,000	March 16, 2020	4.21	$	3.20	$	1.61	33,334
50,000	August 15, 2015	4.62	$	0.98	$	0.39	16,667
750,000	October 21, 2020	4.81	$	0.87	$	0.33	187,500
550,000	October 28, 2020	4.83	$	0.84	$	0.44	550,000
400,000	October 28,2020	4.83	$	0.84	$	0.36	64,000
100,000	December 31, 2020	5.00	$	1.24	$	0.50	33,334
6,675,360							4,272,279

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	December 31, 2015	December 31, 2014

Stock price	$0.822	$1.33
Exercise Price	$0.878	$1.10
Expected life	3.6 years	3.9 years
Expected volatility	67.85%	67.85%
Risk – free interest rate	0.84%	1.32%
Dividend rate	0.00%	0.00%

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values [Table Text Block]

	Nine months ended December 31, 2015 $	Nine months ended December 31, 2014 $

Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	690,885	42,227
Change in fair value of non-employee stock options during the period	(725,520)	739,375

Fair value of non-employee options, end of the period	1,546,809	1,549,481

Share-Based Payments Classified in the Companys Statement of Loss [Table Text Block]

	Three months ended December 31, 2015 $	Nine months ended December 31, 2015 $	Three months ended December 31, 2014 $	Nine months ended December 31, 2014 $

Consulting fees	(36,300)	(45,199)	871,269	1,033,200
Research and development	315,031	57,550	239,463	578,120
Wages and salaries	52,737	419,635	(77,784)	359,025

	331,468	431,986	1,032,948	1,970,345

Schedule of Warrants, Fair Values [Table Text Block]

	Nine months ended December 31, 2015 $	Nine months ended December 31, 2014 $

Fair value of warrants, beginning of the period	-	-
Issuance	739,190	-
Change in fair value of warrants during the period	(387,871)	-

Fair value of warrants, end of the period	351,319	-

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]

	December 31, 2015	December 31, 2014

Stock price	$0.73	-
Exercise Price	$1.44	-
Expected life	3.0 years	-
Expected volatility	67.85%	-
Risk – free interest rate	0.96%	-
Dividend rate	0.00%	-

Schedule of Stockholder's Equity Note Warrants Or Rights Activity [Table Text Block]

	Number of warrants		Weighted Average Exercise Price
	CAD	US	CAD $	US $
Balance March 31, 2015	8,444,400	-	$1.00	-
Granted		1,750,831	-	2.06
Exercised	(14,400)	-	$1.00	-
Balance December 31, 2015	8,430,000	1,750,831	$1.00	2.06

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD $1.00	May 30, 2016
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020
62,878	US $3.00	July 17, 2018
7,545	US $2.15	July 17, 2020
1,041,667	US $1.44	November 10, 2018

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

CONVERTIBLE NOTE (Tables)

9 Months Ended

Dec. 31, 2015

Bifurcation of Embedded Conversion Feature [Table Text Block]


	Nine months ended December 31, 2015 $		Nine months ended December 31, 2014 $
Beginning fair value	-		-
Bifurcation of embedded conversion feature	425,208		-
Settlement of convertible debt	(425,208	)	-
Ending fair value of embedded conversion feature	-		-

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)

3 Months Ended

9 Months Ended

Dec. 31, 2015

Schedule of Error Corrections and Prior Period Adjustments in Statement of Operations [Table Text Block]

	Three months ended December 31, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$1,694,685	($793,495)	$901,190
Research and development	$952,343	$239,463	$1,191,806
Wages and salaries	$603,492	($471,373)	$132,119

Loss from operations	($4,117,423)	$1,025,405	($3,092,018)

Interest and other income	$2,845	$6,570	$9,415
Change in fair value of derivative liability	($55,589)	($20,947)	($76,536)
Foreign exchange	$687,148	($6,570)	$680,578

Net income (loss) for the period	$(3,483,019)	$1,004,458	$(2,478,561)

Comprehensive income (loss) for the period	$(4,190,894)	$1,004,458	$(3,186,436)

Basic and diluted loss per share	$(0.06)	$0.02	$(0.04)

	Nine months ended December 31, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$2,336,051	($1,168,508)	$1,167,543
Research and development	$2,668,529	$527,817	$3,196,346
Wages and salaries	$1,253,494	($569,119)	$684,375

Loss from operations	($8,449,159)	$1,209,810	($7,239,349)

Change in fair value of derivative liability	($818,382)	$147,592	($670,790)

Net loss for the period	$(9,156,043)	$1,357,402	$(7,798,641)

Comprehensive loss for the period	$(9,551,073)	$1,357,402	$(8,193,671)

Basic and diluted loss per share	$(0.17)	$0.03	$(0.14)

RESTATEMENT OF PREVIOUSLY ISSUED AND RESTATED FINANCIAL STATEMENTS (Tables)

3 Months Ended

9 Months Ended

Dec. 31, 2015

Schedule of Error Corrections and Prior Period Adjustments in Condensed Consolidated Financial Statements[Table Text Block]

	Three months ended December 31, 2015
	As reported after first restatement	Adjustment	As restated

Change in fair value of derivative liability	$(261,802)	$(31,896)	$(293,698)

Net loss for the period	($2,400,539)	$(31,896)	$(2,432,435)

Comprehensive loss for the period	$(2,764,335)	$(31,896)	$(2,796,231)

Basic gain (loss) per share	($0.04)	$-	($0.04)

Diluted gain (loss) per share	($0.04)	$-	($0.04)

	Nine months ended December 31, 2015
	As reported	Adjustment	As restated

Change in fair value of derivative liability	$1,627,844	$485,547	$2,113,391

Net loss for the period	($3,537,039)	$485,547	$(3,051,492)

Comprehensive loss for the period	$(4,427,728)	$485,547	$(3,942,181)

Basic gain (loss) per share	($0.05)	$-	($0.05)

Diluted gain (loss) per share	($0.07)	$0.01	($0.06)

Schedule Of Error Corrections And Prior Period Adjustments Text Block [Table Text Block]

	As at December 31, 2015
	As reported after first restatement	Adjustment	As Restated
Derivative liability	$830,378	$67,750	$898,128
Common stock	$20,658,387	$(532,523)	$20,125,864
Additional paid-in capital	$2,175,973	$(20,774)	$2,155,199
Accumulated deficit	$(22,960,490)	$485,547	$(22,474,943)

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	Dec. 31, 2015 USD ($)
Significant Accounting Policies 1	$ 3,051,492
Significant Accounting Policies 2	22,474,943
Significant Accounting Policies 3	19,423,451
Significant Accounting Policies 4	4,350,350
Significant Accounting Policies 5	$ 418,893
Significant Accounting Policies 6	19,633,969

CONVERTIBLE DEBENTURE (Narrative) (Details)	9 Months Ended
CONVERTIBLE DEBENTURE (Narrative) (Details)	Dec. 31, 2015 USD ($)
Convertible Debenture 1	8.00%
Convertible Debenture 2	$ 1,000,100
Convertible Debenture 3	85.00%
Convertible Debenture 4	$ 176,488

PROMISSORY NOTE (Narrative) (Details)	9 Months Ended
PROMISSORY NOTE (Narrative) (Details)	Dec. 31, 2015 USD ($) shares
Promissory Note 1	$ 200,000
Promissory Note 2	6.00%
Promissory Note 3	10.00%
Promissory Note 4 \| shares	30,000
Promissory Note 5 \| shares	30,000
Promissory Note 6	30,000
Promissory Note 7	$ 23,959
Promissory Note 8	$ 1,644

COMMON STOCK (Narrative) (Details)	9 Months Ended
COMMON STOCK (Narrative) (Details)	Dec. 31, 2015 USD ($) $ / shares shares
Common Stock 1	$ 1,825,937
Common Stock 2 \| shares	849,273
Common Stock 3	$ 2.15
Common Stock 4 \| $ / shares	$ 3.00
Common Stock 5	$ 84,074
Common Stock 6	27,396
Common Stock 7 \| $ / shares	$ 3.00
Common Stock 8	$ 721,243
Common Stock 9 \| shares	335,463
Common Stock 10	$ 2.15
Common Stock 11 \| $ / shares	$ 3.00
Common Stock 12	$ 40,803
Common Stock 13	18,978
Common Stock 14 \| $ / shares	$ 2.15
Common Stock 15	$ 270,375
Common Stock 16 \| shares	125,756
Common Stock 17	$ 2.15
Common Stock 18 \| $ / shares	$ 3.00
Common Stock 19	$ 16,223
Common Stock 20	7,545
Common Stock 21 \| $ / shares	$ 2.15
Common Stock 22	$ 7,000,000
Common Stock 23	2,000,000
Common Stock 24	$ 5,000,000

SHARE BASED PAYMENTS (Narrative) (Details)	9 Months Ended
SHARE BASED PAYMENTS (Narrative) (Details)	Dec. 31, 2015 shares
Blah 2	12,108,016
Blah 147	1,750,931

CONVERTIBLE NOTE (Narrative) (Details)	9 Months Ended
CONVERTIBLE NOTE (Narrative) (Details)	Dec. 31, 2015 USD ($) yr $ / shares shares
Convertible Note 1	$ 7,000,000
Convertible Note 2	2,000,000
Convertible Note 3	$ 5,000,000
Convertible Note 4	6.00%
Convertible Note 5	$ 5,000,000
Convertible Note 6	$ 2,000,000
Convertible Note 7 \| $ / shares	$ 0.96
Convertible Note 8	$ 1.44
Convertible Note 9	50.00%
Convertible Note 10	$ 5,000,000
Convertible Note 11 \| $ / shares	$ 0.90
Convertible Note 12 \| $ / shares	$ 1.35
Convertible Note 13	$ 2,000,000
Convertible Note 14	0.73
Convertible Note 15	$ 0.9877
Convertible Note 16 \| yr	1.33
Convertible Note 17	103.64%
Convertible Note 18	0.3677%
Convertible Note 19	$ 425,208
Convertible Note 20	$ 2,000,000
Convertible Note 21 \| shares	2,083,333
Convertible Note 22 \| $ / shares	$ 0.96
Convertible Note 23 \| shares	1,041,667
Convertible Note 24	$ 1.44
Convertible Note 25	268,334
Convertible Note 26	$ 5,000,000
Convertible Note 27 \| shares	5,555,556
Convertible Note 28 \| shares	2,777,778
Convertible Note 29	$ 1.35
Convertible Note 30	$ 5,000,000

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - 9 months ended Dec. 31, 2015	USD ($) d shares	EUR (€) d shares
Commitments And Contingencies 1 \| shares	16,035,026	16,035,026
Commitments And Contingencies 2	4.00%	4.00%
Commitments And Contingencies 3	$ 499,000
Commitments And Contingencies 4	1,065,000
Commitments And Contingencies 5	1,389,000
Commitments And Contingencies 6	586,000
Commitments And Contingencies 7	$ 4,708,223
Commitments And Contingencies 8 \| d	30	30
Commitments And Contingencies 9	$ 300,000
Commitments And Contingencies 10	1,608,235
Commitments And Contingencies 11	2,226,283
Commitments And Contingencies 12	225,000
Commitments And Contingencies 13 \| €		€ 57,000
Commitments And Contingencies 14	$ 2,000,000

RELATED PARTY TRANSACTIONS (Narrative) (Details)	9 Months Ended
RELATED PARTY TRANSACTIONS (Narrative) (Details)	Dec. 31, 2015 USD ($)
Related Party Transactions 1	$ 295,848
Related Party Transactions 2	63,524
Related Party Transactions 3	38,367
Related Party Transactions 4	351,878
Related Party Transactions 5	271,944
Related Party Transactions 6	388,800
Related Party Transactions 7	94,954
Related Party Transactions 8	$ 48,009

SOLE-SOURCE COST-SHARING AGREEMENT (Narrative) (Details)	9 Months Ended
	Dec. 31, 2015 USD ($) d
Soul Source Cost Sharing Agreement 1	$ 2,996,244
Soul Source Cost Sharing Agreement 2	62.00%
Soul Source Cost Sharing Agreement 3	$ 1,372,821
Soul Source Cost Sharing Agreement 4 \| d	30

SUPPLEMENTAL CASH FLOW INFORMATION (Narrative) (Details)	9 Months Ended
	Dec. 31, 2015 USD ($) shares
Supplemental Cash Flow Information 1 \| shares	30,000
Supplemental Cash Flow Information 2	$ 23,959
Supplemental Cash Flow Information 3 \| shares	2,083,333
Supplemental Cash Flow Information 4	$ 1,525,000
Supplemental Cash Flow Information 5	$ 2,000,000
Supplemental Cash Flow Information 6	1,041,667
Supplemental Cash Flow Information 7	$ 206,667
Supplemental Cash Flow Information 5	$ 690,885
Supplemental Cash Flow Information 6 \| shares	2,564,705
Supplemental Cash Flow Information 7	$ 1,000,100
Supplemental Cash Flow Information 8	176,488
Supplemental Cash Flow Information 9	$ 162,890

Fair Value, by Balance Sheet Grouping (Details)	9 Months Ended
Fair Value, by Balance Sheet Grouping (Details)	Dec. 31, 2015 USD ($) shares
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 1	$ 1,581,444
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 2 \| shares	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 3	$ 0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 4	767,879
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 5	690,885
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 6	42,227
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 7	(1,725,520)
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 8	670,790
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 9	546,809
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 10	$ 1,480,896

Schedule of Conversions of Stock (Details)	9 Months Ended
Schedule of Conversions of Stock (Details)	Dec. 31, 2015 USD ($)
Significant Accounting Policies Embedded Conversion Feature 1	$ 0
Significant Accounting Policies Embedded Conversion Feature 2	0
Significant Accounting Policies Embedded Conversion Feature 3	425,208
Significant Accounting Policies Embedded Conversion Feature 4	0
Significant Accounting Policies Embedded Conversion Feature 5	(425,208)
Significant Accounting Policies Embedded Conversion Feature 6	0
Significant Accounting Policies Embedded Conversion Feature 7	0
Significant Accounting Policies Embedded Conversion Feature 8	$ 0

Schedule of Fair Value of Warrants (Details)	9 Months Ended
Schedule of Fair Value of Warrants (Details)	Dec. 31, 2015 USD ($)
Significant Accounting Policies Schedule Of Fair Value Of Warrants 1	$ 0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 2	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 3	739,190
Significant Accounting Policies Schedule Of Fair Value Of Warrants 4	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 5	(387,871)
Significant Accounting Policies Schedule Of Fair Value Of Warrants 6	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 7	351,319
Significant Accounting Policies Schedule Of Fair Value Of Warrants 8	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 9	898,128
Significant Accounting Policies Schedule Of Fair Value Of Warrants 10	$ 1,480,896

Schedule of Earnings Per Share, Basic and Diluted (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 1	$ (2,432,435)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 2	(2,478,561)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 3	(3,051,492)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 4	(7,798,641)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 5	64,958,069
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 6	63,104,788
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 7	64,646,096
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 8	$ 55,066,317
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 9	(0.04)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 10	(0.04)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 11	(0.05)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 12	(0.14)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 13	$ (2,432,435)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 14	(2,478,561)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 15	(3,051,492)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 16	(7,798,641)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 17	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 18	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 19	(1,094,449)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 20	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 21	(2,432,435)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 22	(2,478,561)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 23	(4,145,941)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 24	(7,798,641)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 25	64,958,069
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 26	63,104,788
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 27	64,646,096
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 28	55,066,317
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 29	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 30	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 31	534,822
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 32	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 33	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 34	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 35	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 36	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 37	64,958,069
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 38	63,104,788
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 39	65,180,918
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 40	$ 55,066,317
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 41	(0.04)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 42	(0.04)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 43	(0.06)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 44	(0.14)

Schedule of Share-based Compensation, Stock Options, Activity (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Blah 1 1	$ 4,920,000
Blah 1 2	1.14
Blah 1 3	$ 10,120,000
Blah 1 4	$ (94,640)
Blah 1 5	0.60
Blah 1 6	$ 0
Blah 1 7	$ 1,850,000
Blah 1 8	0.88
Blah 1 9	$ 0
Blah 1 10	$ 6,675,360
Blah 1 11	1.08
Blah 1 12	$ 2,588,702
Blah 1 13	$ 4,272,279
Blah 1 14	1.16
Blah 1 15	$ 1,637,490

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Blah 2 1	$ 3,520,000
Blah 2 2	3.46
Blah 2 3	0.60
Blah 2 4	0.23
Blah 2 5	$ 2,346,667
Blah 2 6	$ 155,360
Blah 2 7	3.46
Blah 2 8	0.60
Blah 2 9	0.23
Blah 2 10	$ 124,110
Blah 2 11	$ 100,000
Blah 2 12	1.54
Blah 2 13	2.52
Blah 2 14	1.06
Blah 2 15	$ 100,000
Blah 2 16	$ 450,000
Blah 2 17	3.94
Blah 2 18	2.92
Blah 2 19	1.65
Blah 2 20	$ 450,000
Blah 2 21	$ 100,000
Blah 2 22	3.94
Blah 2 23	2.92
Blah 2 24	1.49
Blah 2 25	$ 66,667
Blah 2 26	$ 400,000
Blah 2 27	3.94
Blah 2 28	2.96
Blah 2 29	1.56
Blah 2 30	$ 300,000
Blah 2 31	$ 100,000
Blah 2 32	4.21
Blah 2 33	3.20
Blah 2 34	1.61
Blah 2 35	$ 33,334
Blah 2 36	$ 50,000
Blah 2 37	4.62
Blah 2 38	0.98
Blah 2 39	0.39
Blah 2 40	$ 16,667
Blah 2 41	$ 750,000
Blah 2 42	4.81
Blah 2 43	0.87
Blah 2 44	0.33
Blah 2 45	$ 187,500
Blah 2 46	$ 550,000
Blah 2 47	4.83
Blah 2 48	0.84
Blah 2 49	0.44
Blah 2 50	$ 550,000
Blah 2 51	$ 400,000
Blah 2 52	4.83
Blah 2 53	0.84
Blah 2 54	0.36
Blah 2 55	$ 64,000
Blah 2 56	$ 100,000
Blah 2 57	5.00
Blah 2 58	1.24
Blah 2 59	0.50
Blah 2 60	$ 33,334
Blah 2 61	6,675,360
Blah 2 62	$ 4,272,279

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	9 Months Ended
	Dec. 31, 2015 USD ($) yr
Blah 3 1	$ 0.822
Blah 3 2	1.33
Blah 3 3	0.878
Blah 3 4	$ 1.10
Blah 3 5 \| yr	3.6
Blah 3 6 \| yr	3.9
Blah 3 7	67.85%
Blah 3 8	67.85%
Blah 3 9	0.84%
Blah 3 10	1.32%
Blah 3 11	0.00%
Blah 3 12	0.00%

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Blah 4 1	$ 1,581,444
Blah 4 2	0
Blah 4 3	0
Blah 4 4	767,879
Blah 4 5	690,885
Blah 4 6	42,227
Blah 4 7	(725,520)
Blah 4 8	739,375
Blah 4 9	1,546,809
Blah 4 10	$ 1,549,481

Share-Based Payments Classified in the Companys Statement of Loss (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Blah 5 1	$ (36,300)
Blah 5 2	(45,199)
Blah 5 3	871,269
Blah 5 4	1,033,200
Blah 5 5	315,031
Blah 5 6	57,550
Blah 5 7	239,463
Blah 5 8	578,120
Blah 5 9	52,737
Blah 5 10	419,635
Blah 5 11	(77,784)
Blah 5 12	359,025
Blah 5 13	331,468
Blah 5 14	431,986
Blah 5 15	1,032,948
Blah 5 16	$ 1,970,345

Schedule of Warrants, Fair Values (Details)	9 Months Ended
Schedule of Warrants, Fair Values (Details)	Dec. 31, 2015 USD ($)
Blah 10 1	$ 0
Blah 10 2	0
Blah 10 3	739,190
Blah 10 4	0
Blah 10 5	(387,871)
Blah 10 6	0
Blah 10 7	351,319
Blah 10 8	$ 0

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions (Details)	9 Months Ended
	Dec. 31, 2015 USD ($) yr
Blah 11 1	$ 0.73
Blah 11 2	0
Blah 11 3	1.44
Blah 11 4	$ 0
Blah 11 5 \| yr	3
Blah 11 6	$ 0
Blah 11 7	67.85%
Blah 11 8	$ 0
Blah 11 9	0.96%
Blah 11 10	$ 0
Blah 11 11	0.00%
Blah 11 12	$ 0

Schedule of Stockholder's Equity Note Warrants Or Rights Activity (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Blah 6 1	$ 8,444,400
Blah 6 2	0
Blah 6 3	1.00
Blah 6 4	0
Blah 6 5	1,750,831
Blah 6 6	$ 0
Blah 6 7	2.06
Blah 6 8	$ (14,400)
Blah 6 9	0
Blah 6 10	1.00
Blah 6 11	0
Blah 6 12	8,430,000
Blah 6 13	1,750,831
Blah 6 14	$ 1.00
Blah 6 15	2.06

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - 9 months ended Dec. 31, 2015	USD ($)	CAD ($)
Blah 9 1	$ 8,430,000
Blah 9 2		$ 1.00
Blah 9 3	452,032
Blah 9 4	3.00
Blah 9 5	167,731
Blah 9 6	3.00
Blah 9 7	18,978
Blah 9 8	2.15
Blah 9 9	62,878
Blah 9 10	3.00
Blah 9 11	7,545
Blah 9 12	2.15
Blah 9 13	1,041,667
Blah 9 14	$ 1.44

Bifurcation of Embedded Conversion Feature (Details)	9 Months Ended
Bifurcation of Embedded Conversion Feature (Details)	Dec. 31, 2015 USD ($)
Convertible Note Bifurcation Of Embedded 1	$ 0
Convertible Note Bifurcation Of Embedded 2	0
Convertible Note Bifurcation Of Embedded 3	425,208
Convertible Note Bifurcation Of Embedded 4	0
Convertible Note Bifurcation Of Embedded 5	(425,208)
Convertible Note Bifurcation Of Embedded 6	0
Convertible Note Bifurcation Of Embedded 7	0
Convertible Note Bifurcation Of Embedded 8	$ 0

Schedule of Error Corrections and Prior Period Adjustments in Statement of Operations (Details) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2015
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 1	$ 1,694,685
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 2	793,495
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 3	901,190
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 4	952,343
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 5	239,463
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 6	1,191,806
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 7	603,492
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 8	471,373
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 9	132,119
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 10	4,117,423
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 11	1,025,405
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 12	3,092,018
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 13	2,845
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 14	6,570
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 15	9,415
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 16	55,589
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 17	20,947
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 18	76,536
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 19	687,148
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 20	6,570
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 21	680,578
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 22	(3,483,019)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 23	1,004,458
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 24	(2,478,561)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 25	(4,190,894)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 26	1,004,458
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 27	(3,186,436)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 28	(0.06)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 29	0.02
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 30	$ (0.04)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 1		$ 2,336,051
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 2		1,168,508
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 3		1,167,543
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 4		2,668,529
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 5		527,817
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 6		3,196,346
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 7		1,253,494
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 8		569,119
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 9		684,375
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 10		8,449,159
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 11		1,209,810
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 12		7,239,349
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 13		818,382
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 14		147,592
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 15		670,790
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 16		(9,156,043)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 17		1,357,402
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 18		(7,798,641)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 19		(9,551,073)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 20		1,357,402
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 21		(8,193,671)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 22		(0.17)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 23		0.03
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 24		$ (0.14)

Schedule of Error Corrections and Prior Period Adjustments in Condensed Consolidated Financial Statements[Table Text Block] (Details) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2015
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 1	$ (261,802)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 2	(31,896)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 3	(293,698)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 4	2,400,539
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 5	(31,896)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 6	(2,432,435)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 7	(2,764,335)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 8	(31,896)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 9	(2,796,231)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 10	0.04
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 11	0
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 12	0.04
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 13	0.04
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 14	0
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 15	$ 0.04
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 1		$ 1,627,844
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 2		485,547
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 3		2,113,391
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 4		3,537,039
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 5		485,547
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 6		(3,051,492)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 7		(4,427,728)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 8		485,547
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 9		(3,942,181)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 10		0.05
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 11		0
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 12		0.05
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 13		0.07
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 14		0.01
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Condensed Consolidated Financial Statement 15		$ 0.06

Schedule Of Error Corrections And Prior Period Adjustments Text Block (Details)	9 Months Ended
	Dec. 31, 2015 USD ($)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 1	$ 830,378
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 2	67,750
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 3	898,128
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 4	20,658,387
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 5	(532,523)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 6	20,125,864
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 7	2,175,973
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 8	(20,774)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 9	2,155,199
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 10	(22,960,490)
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 11	485,547
Restatement Of Previously Issued And Restated Financial Statements Schedule Of Error Corrections And Prior Period Adjustments Text Block 12	$ (22,474,943)